Strategic Mergers and Upcoming CNR-401 Research Showcase at ALS/MND Symposium
- Canurta
- Nov 28
- 1 min read
Merger with PharmaDrug Progresses Towards Closing
Following the execution of a definitive agreement in Q4, Canurta continues to work toward the initial closing of its strategic merger with PharmaDrug Inc. (CSE: PHRX.CN). This agreement is a key component of Canurta’s growth strategy and public market alignment, supporting operational scale and long-term capital planning.
Extraction Acquisition Target Under Review
In parallel, Canurta is progressing toward a definitive agreement with an extraction company, building on a previously signed Letter of Intent.
This merger is expected to support scalable manufacturing and integration of mobile extraction technology, aligning with Canurta’s operational strategy and clinical development roadmap.
CNR-401 Research to Be Presented at 2025 International ALS/MND Symposium
From December 5–7, 2025, Canurta will present new preclinical findings on CNR-401 at the 36th International Symposium on ALS/MND as part of the in-person poster session. The research highlights results from zebrafish, Drosophila, and mouse models of ALS, including improvements in motor behavior, modulation of neuroinflammatory and repair-related pathways, and survival benefits in fly models.
CNR-401 also demonstrated blood-brain barrier penetration and a favorable safety profile in mouse toxicology studies.
Polykye Platform Advances: New Workflow Developments
Canurta’s Polykye platform continues to advance its discovery capabilities. This month, the R&D team initiated new workflows to enable prenylation across its polyphenol library, opening new directions for compound optimization. These upgrades are designed to enhance the pharmacological potential of flavonoid candidates and accelerate the platform’s drug development output.
